Immunotherapy Drugs (Monoclonal Antibodies, Immunomodulators, Vaccine) Market Size, Share & Trends Analysis and Growth Forecasts, 2025-2030
Immunotherapy Drugs Market
Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Immunotherapy Drugs Market Size, Share & Trends Analysis Report by Drug Type (Monoclonal Antibodies, Immunomodulators, Vaccine), Indication (Autoimmune Diseases, Infectious Diseases, Cancer), Region, with Growth Forecasts, 2025-2030" has been added to ResearchAndMarkets.com's offering.
The Immunotherapy Drugs Market is poised for explosive growth, escalating from USD 257.60 Billion in 2024 to an anticipated USD 486.36 Billion by 2030, reflecting a robust CAGR of 11.20%
This growth trajectory is underpinned by heightened awareness of chronic conditions such as cancer, autoimmune, inflammatory, and infectious diseases, coupled with favorable government policies facilitating drug approval pathways. The increasing adoption of targeted therapies for chronic disease management is further amplifying the market demand for immunotherapy drugs.
Remarkable advancements in the sector include the U.S. approval of Enhertu (trastuzumab) for HER2-positive breast cancer by AstraZeneca and Daiichi Sankyo in May 2022, and the EU's endorsement of F. Hoffmann-La Roche Ltd.'s Tecentriq for NSCLC in June 2022. Simultaneously, expanded research and development, particularly in emerging markets, aligns with industry growth strategies. Novartis AG's collaboration with BeiGene, Ltd. for ociperlimab in December 2021 exemplifies such strategic R&D initiatives to broaden their immune-oncology pipeline.
Boosting market impetus is Pfizer, Inc.'s positive phase 2b/3 trial outcomes for ritlecitinib, targeting alopecia areata, shared in August 2021. The global rise in cancer incidences further propels the demand for immunotherapy solutions. According to Globocan, 19.3 million new oncology cases were recorded in 2020, with projections indicating a 21% rise in European cancer incidences by 2040, as per the European Society of Medical Oncology, thus heightening the need for effective immunotherapy drugs.
Immunotherapy Drugs Market Report Highlights
The monoclonal antibodies segment dominated with a massive 76.2% market share in 2024, driven by extensive R&D and favorable government initiatives.
Demand for biologics treatments for chronic diseases like cardiovascular, respiratory, and autoimmune disorders is a primary growth driver.
The cancer segment commanded a 91.4% market revenue share in 2024, fueled by a surge in global cancer cases and better healthcare infrastructure in developing regions.
North America led the global immunotherapy market, holding a 49.9% revenue share in 2024, attributed to high immunotherapy adoption, favorable reimbursement policies, and increased healthcare investment.
Why Should You Buy This Report?
Comprehensive Market Analysis: Gain detailed insights into key regional and segmental dynamics.
Competitive Landscape: Understand the positioning of leading players in the market.
Future Trends: Uncover trends and drivers influencing market direction.
Actionable Recommendations: Leverage insights to identify new revenue opportunities and inform strategic directions.
Key Attributes:
Report Attribute
Details
No. of Pages
100
Forecast Period
2024 - 2030
Estimated Market Value (USD) in 2024
$257.6 Billion
Forecasted Market Value (USD) by 2030
$486.36 Billion
Compound Annual Growth Rate
11.2%
Regions Covered
Global
Companies Featured
Amgen Inc.
Novartis AG
AbbVie Inc.
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Johnson & Johnson Services, Inc.
AstraZeneca
GSK plc.
Sanofi
Bayer AG
For more information about this report visit https://www.researchandmarkets.com/r/btbjr8
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Immunotherapy Drugs Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UPI
2 hours ago
- UPI
Trump delivers immigration message on Scotland visit
1 of 3 | President Donald Trump played golf in Scotland Saturday morning, teeing it up at his Trump Turnberry golf resort ahead of meetings with European lawmakers and delivering a message after leaving the White House on Friday (pictured). Photo by Will Oliver/UPI | License Photo July 26 (UPI) -- President Donald Trump played golf in Scotland Saturday morning, teeing it up at his Trump Turnberry golf resort ahead of meetings with European lawmakers and delivering a message. "I say two things to Europe: Stop the windmills. You're ruining your countries. I really mean it, it's so sad. You fly over and you see these windmills all over the place, ruining your beautiful fields and valleys and killing your birds," Trump told reporters after arriving on Friday. "On immigration, you better get your act together. You're not going to have Europe any more," he said. Trump is scheduled to discuss trade during a Monday meeting with British Prime Minister Keir Starmer and Scottish First Minister John Swinney. He is also expected to meet with European Commission president Ursula von der Leyen during the four-day visit to Scotland. The delegation will start arriving Saturday and include European trade commissioner Maros Sefcovic, as well as von der Leyen, who Trump referred to as a "highly respected woman." U.S. officials and their EU counterparts are continuing attempts to reach a deal before an Aug. 1 deadline that will see 30% reciprocal tariffs take effect on all EU member states. The United States and Britain reached a deal in June on tariffs between the two countries, although Trump and Starmer were expected to iron out details during their meeting. Protestors demonstrated against Trump's visit in both Edinburgh and Aberdeen Saturday morning, including outside the Trump-owned golf course. He will also visit another of his privately-owned courses, Trump International Scotland in Aberdeenshire, during the trip. "We are really excited, across this whole weekend, there's so many campaign groups turning out in the streets, taking in action in their communities or at rallies like this. It's kind of like a carnival of resistance," demonstrator Anita Bhadani told the BBC outside of the U.S. Consulate General's office in Edinburgh Saturday, after helping to organize the Stop Trump Coalition. The coalition said its purpose is to "defeat the politics of Trumpism, and to promote an alternative, democratic vision of the world based on peace, social justice and international cooperation."
Business Upturn
5 hours ago
- Business Upturn
RXST STOCK UPDATE: RxSight, Inc. (NASDAQ:RXST) is being Sued for Securities Fraud – Contact BFA Law by September 22 Class Action Deadline
By GlobeNewswire Published on July 26, 2025, 16:07 IST NEW YORK, July 26, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: Investors have until September 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities. The case is pending in the U.S. District Court for the Central District of California and is captioned Makaveev v. RxSight, Inc., et al. , No. 25-cv- 01596. Why Was RxSight Sued for Securities Fraud? RxSight is engaged in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery along with capital equipment used with the lenses. The Company's main product is its Light Adjustable Lens (LAL) that can be customized after cataract surgery through a series of non-invasive light treatments. These treatments, using a Light Delivery Device (LDD), adjust the lens's shape and power to optimize vision based on the patient's individual needs and preferences. During the relevant period, the Company touted its strong LAL and LDD sales and failed to disclose 'adoption challenges' in its products. In reality, RxSight was experiencing a slowdown in LAL utilization that was first noted in 2024. The Stock Declines as the Truth Is Revealed On April 3, 2025, before the market opened, RxSight cut its 2025 full-year revenue forecast citing a 'softening' of the market that purportedly occurred 'in the second half of 2024.' On this news, the price of RxSight stock declined roughly 38%, from $26.12 per share on April 2, 2025, to $16.21 per share on April 3, 2025. Then on July 8, 2025, the Company further cut its 2025 full-year revenue forecast. RxSight attributed the adjustment to 'the slower ramp in LAL utilization that was first noted in 2024' and '[a]doption challenges over the last few quarters.' On this news, the price of RxSight stock declined roughly 38%, from $12.79 per share on July 8, 2025, to $7.95 per share on July 9, 2025. Click here for more information: What Can You Do? If you invested in RxSight you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA , The Legal 500 , and ISS SCAS , and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal , among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon , 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
5 hours ago
- Business Upturn
As XRP Crosses $200 Billion Market Cap, HashJ Expands Support for Scalable XRP & Dogecoin Contract Rewards
London, United Kingdom, July 26, 2025 (GLOBE NEWSWIRE) — In response to XRP officially surpassing a $200 billion market capitalization, MGPD Finance Limited, doing business as HashJ, today announced the expansion of its mobile-based digital contract platform to further support XRP and Dogecoin-based reward systems. The platform allows everyday users to engage with the fast-growing digital asset economy—now including XRP-linked reward strategies and Dogecoin contract participation—entirely from their smartphones. This announcement reflects HashJ's continued mission to make crypto-based income tools more accessible and transparent to mainstream users. This article will deeply analyze the contract methods of these two digital assets and introduce how the HashJ platform makes it easy for every ordinary person to experience it. New users can visit the HashJ official website ( to register for free and receive a $118 gift package (including $100 trial money and $18 real rewards) to start the contract journey immediately. The XRP Challenge: Why Traditional Rewards Systems Fall Short XRP, developed by Ripple Labs, does not rely on Proof of Work or traditional blockchain-based reward systems. Unlike Dogecoin or Bitcoin, XRP does not support contract-driven earning mechanisms natively, due to its pre-issued total supply and consensus protocol based on validation nodes rather than computational method. To address this limitation, HashJ now offers XRP-related yield options via remote smart contract systems and diversified asset rewards—allowing users to engage with XRP's growth ecosystem even in the absence of contract-based mechanisms. Dogecoin Contracts: Still A High-Value Option in 2025 In contrast to XRP, Dogecoin remains a powerful option for daily crypto income. Through its Scrypt-based algorithm and merged structure with Litecoin, Dogecoin contract systems continue to deliver accessible and stable returns. Even without hardware, users can now access DOGE-linked rewards through HashJ's earning contracts: Daily income potential averaging 75 DOGE Net profit approximating $12.20/day with remote access No hardware or setup required—fully integrated mobile experience How HashJ Simplifies the Crypto Rewards Process Founded in 2018, HashJ is a global mobile-first platform that enables users to access crypto contract earnings with no prior technical background. The system supports BTC, ETH, DOGE, and XRP-related reward methods and is purpose-built for mobile access, remote management, and real-time daily income tracking. Key Benefits of HashJ's Contract Model: No hardware required – entirely app-based – entirely app-based Smart revenue automation – optimized by AI-based allocation – optimized by AI-based allocation Flexible entry points – users can start with as little as $10 – users can start with as little as $10 Zero risk onboarding – free $118 starter pack for new users Why choose HashJ'a contract system? In celebration of XRP's latest market milestone and growing Dogecoin contract demand, HashJ has launched the following upgrades for new registrants: $100 trial credit for contract experience for contract experience $18 in real crypto funds for immediate use for immediate use Access to XRP yield options, DOGE daily contracts, and multi-coin flexibility This total of $118 start-up funds is completely free, allowing every new user to participate in digital asset contracts with zero risk and achieve steady income. HashJ's Commitment to Broader Participation With the addition of XRP-focused rewards and stable DOGE-based contracts, MGPD Finance Limited (HashJ) continues to lead innovation in digital income tools. The platform is now used by over 2 million users globally and is positioned to support the next wave of crypto adoption across mobile and emerging markets. 'Crypto participation should be as easy as downloading an app,' said a spokesperson for HashJ. 'Our mission is to help everyday people build reliable digital income streams—even from assets like XRP that don't traditionally offer contract-based returns.' How To Start Your Digital Income Journey MGPD Finance Limited invites users to explore the new generation of smart contract tools that provide simple, secure, and consistent earning strategies across XRP, DOGE, and other leading assets. Register today at to claim your $118 starter bonus and begin earning from anywhere, anytime—no hardware, no experience, just results. About MGPD Finance Limited (doing business as hashj) Founded in 2018, MGPD Finance Limited (doing business as HashJ) is the world's leading mobile contract platform, dedicated to making it easy for everyone to participate in the income ecosystem of mainstream digital currencies. Users can sign contracts for BTC, ETH, DOGE and other currencies simply through their mobile phones. The platform operation is extremely simple and suitable for zero-based users. One-click operation, no technical background is required, you can start the digital asset income experience. For more information, visit: Download: Available on iOS and Android Business Inquiries: [email protected]
